Please login to the form below

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Roche’s Polivy for B-cell lymphoma

drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... The new treatment option is great news for patients and clinicians, considering that the prognosis for relapsed

Latest news

IMV preps pivotal trials for ovarian cancer T cell therapy

B-cell lymphoma (DLBCL) and another spanning multiple solid tumour types.
EU grants conditional approval to Roche's lymphoma drug Polivy

The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and CLL. ... MorphoSys has already filed tafasitamab with the FDA, as a treatment for patients with r/r DLBCL, and expects a decision by mid-2020.
Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). ... Meanwhile, in the same period Yescarta brought in $183m from its use in DLBCL and other B-cell lymphoma types.
Gracell reports impressive data with one-day CAR-T for leukaemia

Kymriah is approved for B-ALL as well as diffuse large B-cell lymphoma (DLBCL) – a form of non-Hodgkin’s lymphoma – and made just over $100m in sales in the ... Meanwhile, Gilead reported $216m in first-half sales from DLBCL and another NHL variant

More from news
Approximately 9 fully matching, plus 56 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
Pharma deals in April 2015

its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...